DDInter535 DDInter1082
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
Diazoxide {u} (Compound) palliates {v} (Disease) hypertension
Diazoxide {u} (Compound) downregulates {v} (Gene) GTPBP8
Diazoxide {u} (Compound) causes {v} (Side Effect) Anorexia
Diazoxide (Compound) resembles Chlorothiazide (Compound)
Diazoxide (Compound) binds KCNJ11 (Gene)
Diazoxide (Compound) upregulates PRKCQ (Gene)
Diazoxide (Compound) palliates hypertension (Disease)
Diazoxide (Compound) downregulates GTPBP8 (Gene)
Diazoxide (Compound) causes Anorexia (Side Effect)